[DOI] [PubMed] [Google Scholar] 56.Yoo J.-Y., Yum K.-S
Devanaboyina SC, Khare P, Challa DK, Ober RJ, Ward ES
Now, he says, the interest in peptides puts compounding pharmacies in an area where they start to act like mass drug producers. He says compounding pharmacies have been inspected and regulated by states more than the FDA, and in some cases there have been outcomes where theres been bacterial contamination and issues with quality control and dosing that would typically be caught in a larger manufacturing process but are missed. Our system works really well There isnt enough efficacy and safety data to approve these peptide injectables as traditional drugs, but Zuckerman says that the FDA is facing the reality that a lot of Americans are interested in drugs that they feel probably work and are probably safe
Rennard SI, Bailey KL: Chronic obstructive pulmonary disease exacerbations: accurate and easy measurement promises much
If side effects are persistent, if pancreatitis risk is a concern, or if weight or cardiovascular goals point in another direction, clinicians may consider alternatives from other drug classes
